Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Links

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Cancer Chemotherapy and Pharmacology|February 8, 2006
Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancerPaul L de Souza, Winston Liauw, Matthew Links, et al.
ANZ Journal of Surgery|April 22, 2006
Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapyReema Hadi, Vanessa Saunders, Olga Utkina, et al.
Annals of Surgical Oncology|April 28, 2007
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy CenterTristan D Yan, Matthew Links, Sal Fransi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
Genome|January 27, 2012
Analysis of expressed sequence tags in Brassica napus cotyledons damaged by crucifer flea beetle feedingMargaret Gruber, Limin Wu, Matthew Links, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumorsHui K Gan, Paul L Mitchell, Peter Galettis, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2009
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancerMohammad H Pourgholami, Michael Szwajcer, Melvin Chin, et al.
Pancreas|November 6, 2019
Evaluation of Phase II Trial Design in Advanced Pancreatic CancerMonica Tang, Julia Chen, David Goldstein, et al.
Asia-Pacific Journal of Clinical Oncology|February 22, 2011
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>CEkkaphon Metharom, Peter Galettis, Susan Manners, et al.
Molecular Cancer Therapeutics|January 24, 2007
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinomaTamantha K Stutchbury, Fares Al-Ejeh, Gillian E Stillfried, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|February 8, 2006
Phase I and pharmacokinetic study of weekly NV06 (Phenoxodiol), a novel isoflav-3-ene, in patients with advanced cancerPaul L de Souza, Winston Liauw, Matthew Links, et al.
ANZ Journal of Surgery|April 22, 2006
Review of patients with peritoneal malignancy treated with peritonectomy and heated intraperitoneal chemotherapyReema Hadi, Vanessa Saunders, Olga Utkina, et al.
Annals of Surgical Oncology|April 28, 2007
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy CenterTristan D Yan, Matthew Links, Sal Fransi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
Genome|January 27, 2012
Analysis of expressed sequence tags in Brassica napus cotyledons damaged by crucifer flea beetle feedingMargaret Gruber, Limin Wu, Matthew Links, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumorsHui K Gan, Paul L Mitchell, Peter Galettis, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2009
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancerMohammad H Pourgholami, Michael Szwajcer, Melvin Chin, et al.
Pancreas|November 6, 2019
Evaluation of Phase II Trial Design in Advanced Pancreatic CancerMonica Tang, Julia Chen, David Goldstein, et al.
Asia-Pacific Journal of Clinical Oncology|February 22, 2011
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>CEkkaphon Metharom, Peter Galettis, Susan Manners, et al.
Molecular Cancer Therapeutics|January 24, 2007
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinomaTamantha K Stutchbury, Fares Al-Ejeh, Gillian E Stillfried, et al.
Pageof 5